A citation-based method for searching scientific literature

Carol Aghajanian, Stephanie V Blank, Barbara A Goff, Patricia L Judson, Michael G Teneriello, Amreen Husain, Mika A Sovak, Jing Yi, Lawrence R Nycum. J Clin Oncol 2012
Times Cited: 776



Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote, Noa E Ben-Baruch, Christian Marth, Radosław Mądry, René D Christensen, Jonathan S Berek, Anne Dørum, Anna V Tinker, Andreas du Bois, Antonio González-Martín, Philippe Follana, Benedict Benigno, Per Rosenberg, Lucy Gilbert, Bobbie J Rimel, Joseph Buscema, John P Balser, Shefali Agarwal, Ursula A Matulonis. N Engl J Med 2016
Times Cited: 985




List of shared articles



Times cited

Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM).
Angiolo Gadducci, Giovanni D Aletti, Fabio Landoni, Roberta Lazzari, Giorgia Mangili, Paola Olivas, Sandro Pignata, Vanda Salutari, Enrico Sartori, Giovanni Scambia,[...]. Tumori 2021
1

Impact of BRCA1/2 Mutations on the Efficacy of Secondary Cytoreductive Surgery.
Felipe Leonardo Estati, Rafaela Pirolli, Viviane Teixeira Loiola de Alencar, Adriana Regina Gonçalves Ribeiro, Maria Nirvana Formiga, Giovana Tardin Torrezan, Dirce Maria Carraro, Andrea Paiva Gadelha Guimarães, Glauco Baiocchi, Alexandre André Balieiro Anastácio da Costa. Ann Surg Oncol 2021
3

How to sequence treatment in relapsed ovarian cancer.
Sandro Pignata, Sabrina Chiara Cecere. Future Oncol 2021
1

Current Ovarian Cancer Maintenance Strategies and Promising New Developments.
Vinaya Gogineni, Susan Morand, Hannah Staats, Rachel Royfman, Monika Devanaboyina, Katelyn Einloth, Danielle Dever, Laura Stanbery, Phylicia Aaron, Luisa Manning,[...]. J Cancer 2021
2

SEOM clinical guideline in ovarian cancer (2020).
A Redondo, E Guerra, L Manso, C Martin-Lorente, J Martinez-Garcia, J A Perez-Fidalgo, M Q Varela, M J Rubio, M P Barretina-Ginesta, A Gonzalez-Martin. Clin Transl Oncol 2021
1

A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01).
Yong Jae Lee, Myong Cheol Lim, Byoung Gie Kim, Natalie Yl Ngoi, Chel Hun Choi, Sang Yoon Park, David Sp Tan, Yunjung Go, Jung Yun Lee. J Gynecol Oncol 2021
1

Stiffness increases with myofibroblast content and collagen density in mesenchymal high grade serous ovarian cancer.
Virginie Mieulet, Camille Garnier, Yann Kieffer, Thomas Guilbert, Fariba Nemati, Elisabetta Marangoni, Gilles Renault, Foucauld Chamming's, Anne Vincent-Salomon, Fatima Mechta-Grigoriou. Sci Rep 2021
2

Phase II consolidation trial with anti-Lewis-Y monoclonal antibody (hu3S193) in platinum-sensitive ovarian cancer after a second remission.
Oren Smaletz, Gustavo Ismael, Maria Del Pilar Estevez-Diz, Ivana L O Nascimento, Ana Luiza Gomes de Morais, Geraldo Felício Cunha-Junior, Sergio J Azevedo, Venancio A Alves, Ana Maria Moro, Fernanda P Yeda,[...]. Int J Gynecol Cancer 2021
1

The systemic treatment of recurrent ovarian cancer revisited.
T Baert, A Ferrero, J Sehouli, D M O'Donnell, A González-Martín, F Joly, J van der Velden, P Blecharz, D S P Tan, D Querleu,[...]. Ann Oncol 2021
2

The role of blinded independent radiologic review in ovarian cancer clinical trials: Discerning the value.
Amy Loreen, Clarissa Polen-De, Bradley J Monk, Amanda L Jackson, Caroline C Billingsley, Thomas J Herzog. Gynecol Oncol 2021
0

Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors.
Camilla Nero, Francesca Ciccarone, Antonella Pietragalla, Simona Duranti, Gennaro Daniele, Vanda Salutari, Maria Vittoria Carbone, Giovanni Scambia, Domenica Lorusso. Cancers (Basel) 2021
0

Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review.
Melissa Bradbury, Eva Borràs, Assumpció Pérez-Benavente, Antonio Gil-Moreno, Anna Santamaria, Eduard Sabidó. Cancers (Basel) 2021
0

4-step, 2-h carboplatin desensitization in Japanese patients with ovarian cancer: a prospective study.
Meiko Nishimura, Hideki Sakai, Takuma Onoe, Shogen Boku, Takaaki Yokoyama, Genmu Kadokura, Satoshi Morita, Noriyuki Katsumata, Koji Matsumoto. Int J Clin Oncol 2021
0

Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Angeles Alvarez Secord, David M O'Malley, Anil K Sood, Shannon N Westin, Joyce F Liu. Gynecol Oncol 2021
0

Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.
Haley A Moss, Jessica A Perhanidis, Laura J Havrilesky, Angeles Alvarez Secord. Gynecol Oncol 2021
0

Clinical benefit of systemic therapies for recurrent ovarian cancer-ESMO-MCBS scores.
K E Broekman, M van Kruchten, H van Tinteren, C Sessa, M Jalving, A K L Reyners. ESMO Open 2021
0

Comparisons of survival outcomes between bevacizumab and olaparib in BRCA-mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052).
Se Ik Kim, Jeong Won Lee, Kidong Kim, Maria Lee, Jigeun Yoo, Min Chul Choi, Suhyun Hwangbo, Young Hwa Kwak, Jong Min Lee, So Jin Shin,[...]. J Gynecol Oncol 2021
0

Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment.
Katherine C Kurnit, Gini F Fleming, Ernst Lengyel. Obstet Gynecol 2021
4

Oregovomab: an investigational agent for the treatment of advanced ovarian cancer.
Antonella Pietragalla, Simona Duranti, Gennaro Daniele, Camilla Nero, Francesca Ciccarone, Domenica Lorusso, Anna Fagotti, Giovanni Scambia. Expert Opin Investig Drugs 2021
0

Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer.
Angela Cho, Jeong-Yeol Park, Shin-Wha Lee, Dae-Yeon Kim, Dae-Shik Suh, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim. Arch Gynecol Obstet 2021
0

Recurrent ovarian cancer in the era of poly-ADP ribose polymerase inhibitors: time to re-assess established clinical practices.
M Bartoletti, S C Cecere, L Musacchio, R Sorio, F Puglisi, S Pignata. ESMO Open 2021
0

Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study.
Oliver Zivanovic, Dennis S Chi, Qin Zhou, Alexia Iasonos, Jason A Konner, Vicky Makker, Rachel N Grisham, Amy K Brown, Stacy Nerenstone, John P Diaz,[...]. J Clin Oncol 2021
1

Management of advanced ovarian cancer in Spain: an expert Delphi consensus.
Andres Redondo, Ana Oaknin, Maria Jesus Rubio, Maria-Pilar Barretina-Ginesta, Ana de Juan, Luis Manso, Ignacio Romero, Cristina Martin-Lorente, Andres Poveda, Antonio Gonzalez-Martin. J Ovarian Res 2021
0

A CLEARER VIEW ON OVARIAN CLEAR CELL CARCINOMA.
Aglaja De Pauw, Eline Naert, Koen Van de Vijver, Tummers Philippe, Katrien Vandecasteele, Hannelore Denys. Acta Clin Belg 2021
0

Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer.
Isabelle Ray-Coquard, David Cibula, Mansoor R Mirza, Alexander Reuss, Caterina Ricci, Nicoletta Colombo, Horst Koch, Frédéric Goffin, Antonio González-Martin, Petronella B Ottevanger,[...]. Int J Cancer 2020
8

Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer.
Ezgi Guler, Daniel A Smith, Bhanusupriya Somarouthu, Rahul Gujrathi, Nikhil H Ramaiya, Sree Harsha Tirumani. Abdom Radiol (NY) 2020
2

Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Ling Wang, Qi Wang, Yangchun Xu, Manhua Cui, Liying Han. Curr Drug Targets 2020
5

Targeted therapy clinical trials in ovarian cancer: improved outcomes by gene mutation screening.
Quan Guo, Qing Yang, Jun Li, Guipeng Liu, Igor Nikoulin, Steve Jia. Anticancer Drugs 2020
3

A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.
Ignace Vergote, Florian Heitz, Paul Buderath, Matthew Powell, Jalid Sehouli, Christine M Lee, Anne Hamilton, James Fiorica, Kathleen N Moore, Michael Teneriello,[...]. Gynecol Oncol 2020
13

Latest clinical evidence of maintenance therapy in ovarian cancer.
Christine S Walsh. Curr Opin Obstet Gynecol 2020
11

Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review.
Rebecca Arend, Shannon Neville Westin, Robert L Coleman. Int J Gynecol Cancer 2020
2

[Current advances in immunotherapy in ovarian cancer].
Olivia Le Saux, Bertrand Dubois, Marc-Henri Stern, Magali Terme, Eric Tartour, Jean-Marc Classe, Nicolas Chopin, Olivier Trédan, Christophe Caux, Isabelle Ray-Coquard. Bull Cancer 2020
3


Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors.
Rosemary Lord, Jyoti Rauniyar, Tamsin Morris, Orlaith Condon, Rachel Jones, Rowan Miller, Marcia Hall, Fiona Lofts, Rosalind M Glasspool, Emma Hudson. Int J Gynecol Cancer 2020
2

Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
Michele Bartoletti, Giacomo Pelizzari, Lorenzo Gerratana, Lucia Bortot, Davide Lombardi, Milena Nicoloso, Simona Scalone, Giorgio Giorda, Gustavo Baldassarre, Roberto Sorio,[...]. Int J Mol Sci 2020
6

SOLO 3 Trial: How Do the Results Fit in With Current Evidence?
Eduardo Paulino, Andreia C Melo. J Clin Oncol 2020
1